Xiong H, Mancini M, Gobert M, Shen S, Furtado G, Lira S, Parkhurst C, Brengues M, Tadokoro C, Trimarchi T, Singh A, Khiabanian H, Minuzzo S, Indraccolo S, Lobry C, Aifantis I, Herranz D, Lafaille J, Maraver A Spleen plays a major role in DLL4-driven acute T-cell lymphoblastic leukemia. Theranostics. 2021;11(4):1594-1608. doi:10.7150/thno.48067
Latorzeff I, Sargos P, Créhange G, Azria D, Hasbini A, Dubergé T, Toledano A, Graff-Cailleaud P, Chapet O, Hennequin C, de Crevoisier R, Supiot S, Pasquier D [Indications and outlooks of radiohormonal therapy of high-risk prostate cancers]. Cancer Radiother. Feb 11, 2020. doi:10.1016/j.canrad.2019.06.018
Maria A, Bourgier C, Martinaud C, Borie R, Rozier P, Rivière S, Crestani B, Guilpain P [From fibrogenesis towards fibrosis: Pathophysiological mechanisms and clinical presentations]. Rev Med Interne. Feb 08, 2020. doi:10.1016/j.revmed.2020.01.002
Framery B, Gutowski M, Dumas K, Evrard A, Muller N, Dubois V, Quinonero J, Scherninski F, Pèlegrin A, Cailler F Toxicity and pharmacokinetic profile of SGM-101, a fluorescent anti-CEA chimeric antibody for fluorescence imaging of tumors in patients. Toxicol Rep. 2019;6. doi:10.1016/j.toxrep.2019.04.011
Martineau P, Watier H, Turtoi A Targets for MAbs: innovative approaches for their discovery & validation, LabEx MAbImprove 6th antibody industrial symposium, June 25-26, 2018, Montpellier, France. MAbs. 2019;11(5):812-825. doi:10.1080/19420862.2019.1612691
Seibold P, Webb A, Aguado-Barrera M, Azria D, Brengues M, Briers E, Bultijnck R, Calvo-Crespo P, Carballo A, Choudhury A, Cicchetti A, Claßen J, Delmastro E, Dunning A, Elliott R, Farcy-Jacquet M-P, Gabriele P, Garibaldi E, Gómez-Caamaño A, Gutiérrez-Enríquez S, Higginson D, Johnson K, Lobato-Busto R, Mollà M, Müller A, Payne D, Peleteiro P, Post G, Rancati T, Rattay T, Reyes V, Rosenstein B, De Ruysscher D, De Santis M, Schäfer J, Schnabel T, Sperk E, Symonds R, Stobart H, Taboada-Valladares B, Talbot C, Valdagni R, Vega A, Veldeman L, Ward T, Weißenberger C, West C, Chang-Claude J REQUITE: A prospective multicentre cohort study of patients undergoing radiotherapy for breast, lung or prostate cancer. Radiother Oncol. 2019;138. doi:10.1016/j.radonc.2019.04.034
Lacombe J, Brengues M, Mangé A, Bourgier C, Gourgou S, Pèlegrin A, Ozsahin M, Solassol J, Azria D Quantitative proteomic analysis reveals AK2 as potential biomarker for late normal tissue radiotoxicity. Radiat Oncol. 2019;14(1):142. doi:10.1186/s13014-019-1351-8
Auperin A, Rivera S, Boisselier P, Lang P, Lassau N, Taourel P, Azria D, Bourhis J, Deutsch E, Vozenin M-C Pravastatin Reverses Established Radiation-Induced Cutaneous and Subcutaneous Fibrosis in Patients With Head and Neck Cancer: Results of the Biology-Driven Phase 2 Clinical Trial Pravacur. Int. J. Radiat. Oncol. Biol. Phys.. 2019;104(2):365-373. doi:10.1016/j.ijrobp.2019.02.024
Talbot C, Veldwijk M, Azria D, Batini C, Bierbaum M, Brengues M, Chang-Claude J, Johnson K, Keller A, Smith S, Sperk E, Symonds R, Wenz F, West C, Herskind C Multi-centre technical evaluation of the radiation-induced lymphocyte apoptosis assay as a predictive test for radiotherapy toxicity. Clin Transl Radiat Oncol. 2019;18. doi:10.1016/j.ctro.2019.06.001
Le Clorennec C, Lazrek Y, Dubreuil O, Sampaio C, Larbouret C, Lanotte R, Poul M-A, Barret J-M, Prost J-F, Pèlegrin A, Chardès T ITCH-dependent proteasomal degradation of c-FLIP induced by the anti-HER3 antibody 9F7-F11 promotes DR5/caspase 8-mediated apoptosis of tumor cells. Cell Commun. Signal. 2019;17(1):106. doi:10.1186/s12964-019-0413-8
Boige V, Mollevi C, Gourgou S, Azria D, Seitz J-F, Vincent M, Bigot L, Juzyna B, Miran I, Gerard J-P, Laurent-Puig P Impact of single-nucleotide polymorphisms in DNA repair pathway genes on response to chemoradiotherapy in rectal cancer patients: Results from ACCORD-12/PRODIGE-2 phase III trial. Int. J. Cancer. 2019;145(11):3163-3172. doi:10.1002/ijc.32417
Ashraf Y, Mansouri H, Laurent-Matha V, Alcaraz L, Roger P, Guiu S, Derocq D, Robin G, Michaud H-A, Jarlier M, Pugnière M, Robert B, Puel A, Martin L, Landomiel F, Bourquard T, Achour O, Fruitier-Arnaudin I, Pichard A, Deshayes E, Turtoi A, Poupon A, Boissière-Michot F, Pirot N, Bernex F, Jacot W, du Manoir S, Theillet C, Pouget J-P, Navarro-Teulon I, Bonnefoy N, Pèlegrin A, Chardès T, Martineau P, Liaudet-Coopman E Immunotherapy of triple-negative breast cancer with cathepsin D-targeting antibodies. J Immunother Cancer. 2019;7(1):29. doi:10.1186/s40425-019-0498-z
Bourillon L, Bourgier C, Gaborit N, Garambois V, Llès E, Zampieri A, Ogier C, Jarlier M, Radosevic-Robin N, Orsetti B, Delpech H, Theillet C, Colombo P-E, Azria D, Pèlegrin A, Larbouret C, Chardès T An auristatin-based antibody-drug conjugate targeting HER3 enhances the radiation response in pancreatic cancer. Int. J. Cancer. 2019;145(7):1838-1851. doi:10.1002/ijc.32273
Neiveyans M, Melhem R, Arnoult C, Bourquard T, Jarlier M, Busson M, Laroche A, Cerutti M, Pugnières M, Ternant D, Gaborit N, Chardès T, Poupon A, Gouilleux-Gruart V, Poul M-A A recycling anti-transferrin receptor-1 monoclonal antibody as an efficient therapy for erythroleukemia through target up-regulation and antibody-dependent cytotoxic effector functions. MAbs. Jan 03, 2019. doi:10.1080/19420862.2018.1564510
Ogier C, Colombo P-E, Bousquet C, Canterel-Thouennon L, Sicard P, Garambois V, Thomas G, Gaborit N, Jarlier M, Pirot N, Pugnière M, Vie N, Gongora C, Martineau P, Robert B, Pèlegrin A, Chardès T, Larbouret C Targeting the NRG1/HER3 pathway in tumor cells and cancer-associated fibroblasts with an anti-neuregulin 1 antibody inhibits tumor growth in pre-clinical models of pancreatic cancer. Cancer Lett.. 2018;432. doi:10.1016/j.canlet.2018.06.023
Boogerd L, Hoogstins C, Schaap D, Kusters M, Handgraaf H, van der Valk M, Hilling D, Holman F, Peeters K, Mieog J, van de Velde C, Farina-Sarasqueta A, van Lijnschoten I, Framery B, Pèlegrin A, Gutowski M, Nienhuijs S, de Hingh I, Nieuwenhuijzen G, Rutten H, Burggraaf J, Vahrmeijer A Safety and effectiveness of SGM-101, a fluorescent antibody targeting carcinoembryonic antigen, for intraoperative detection of colorectal cancer: a dose-escalation pilot study. Lancet Gastroenterol Hepatol. 2018;3(3):181-191. doi:10.1016/S2468-1253(17)30395-3
Tosi D, Pérez-Gracia E, Atis S, Gabanou M, Larbouret C, Jarlier M, Mollevi C, Torro A, Del Rio M, Martineau P, Gongora C Rational development of synergistic combinations of chemotherapy and molecular targeted agents for colorectal cancer treatment. BMC Cancer. 2018;18(1):812. doi:10.1186/s12885-018-4712-z
Azria D, Brengues M, Gourgou S Personalizing Breast Cancer Irradiation Using Biology: From Bench to the Accelerator. Front Oncol. 2018;8. doi:10.3389/fonc.2018.00083
Bryden F, Martin C, Letast S, Viéitez-Villemin I, Rousseau A, Colas C, Brachet-Botineau M, Allard-Vannier E, Larbouret C, Viaud-Massuard M-C, Joubert N Impact of cathepsin B-sensitive triggers and hydrophilic linkers on in vitro efficacy of novel site-specific antibody-drug conjugates. Org. Biomol. Chem.. 2018;16(11):1882-1889. doi:10.1039/c7ob02780j
Bourgier C, Castan F, Riou O, Nguyen T-D, Peignaux K, Lemanski C, Lagrange J-L, Kirova Y, Lartigau E, Belkacemi Y, Rivera S, Noël G, Clippe S, Mornex F, Hennequin C, Gourgou S, Brengues M, Fenoglietto P, Ozsahin E, Azria D Impact of adjuvant hormonotherapy on radiation-induced breast fibrosis according to the individual radiosensitivity: results of a multicenter prospective French trial. Oncotarget. 2018;9(21):15757-15765. doi:10.18632/oncotarget.24606
Hoogstins C, Boogerd L, Sibinga Mulder B, Mieog J, Swijnenburg R, van de Velde C, Farina Sarasqueta A, Bonsing B, Pèlegrin A, Gutowski M, Cailler F, Burggraaf J, Vahrmeijer A Image-Guided Surgery in Patients with Pancreatic Cancer: First Results of a Clinical Trial Using SGM-101, a Novel Carcinoembryonic Antigen-Targeting, Near-Infrared Fluorescent Agent. Ann. Surg. Oncol.. 2018;25. doi:10.1245/s10434-018-6655-7
Martin C, Kizlik-Masson C, Pèlegrin A, Watier H, Viaud-Massuard M-C, Joubert N Antibody-drug conjugates: Design and development for therapy and imaging in and beyond cancer, LabEx MAbImprove industrial workshop, July 27-28, 2017, Tours, France. MAbs. 2018;10(2):210-221. doi:10.1080/19420862.2017.1412130
Leconet W, Chentouf M, Chevalier C, Sirevnt A, Ait-Arsa I, Busson M, Jarlier M, Radosevic-Robin N, Theillet C, Chalbos D, Pasquet J, Pelegrin A, Larbouret C, Robert B Therapeutic activity of anti-AXL antibody against triple-negative breast cancer Patient Derived Xenografts and metastasis. Clin Cancer Res. 2017;23. doi:10.1158/1078-0432.CCR-16-1316
Bougherara H, Némati F, Nicolas A, Massonnet G, Pugnière M, Le Frère-Belda M-A, Leary A, Alexandre J, Meseure D, Barret J-M, Navarro-Teulon I, Pèlegrin A, Roman-Roman S, Prost J-F, Donnadieu E, Decaudin D The humanized anti-human AMHRII mAb 3C23K exerts an anti-tumor activity against human ovarian cancer through tumor-associated macrophages. Oncotarget. 2017;8(59):99950-99965. doi:10.18632/oncotarget.21556
Estupina P, Fontayne A, Barret J, Kersual N, Dubreuil O, Le Blay M, Pichard A, Jarlier M, Chauvin M, Chardes T, Pouget J, Deshayes E, Rossignol A, Abache T, de Romeuf C, Terrier A, Verhaeghe L, Gaucher C, Prost J, Pelegrin A, Navarro-Teulon I The anti-tumor efficacy of 3C23K, a glyco-engineered humanized anti-MISRII antibody, in an ovarian cancer model is mainly mediated by engagement of immune effector cells. Oncotarget. 2017;8. doi:10.18632/oncotarget.15715
Institut de Recherche en Cancérologie de
